- Home
- IRAA
IRAA
Iris Acquisition Corp
as 07-26-2024 4:00pm EST
Iris Acquisition Corp is a blank check company.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | GRAND CAYMAN |
| Market Cap: | 80.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 275.0 |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | -64.52 |
| 52 Week Low/High: | $10.30 - $12.49 | Next Earning Date: | 01-06-2023 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Iris Acquisition Corp News
IRAA Breaking Stock News: Dive into IRAA Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
GlobeNewswire
2 months ago
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Business Wire
2 months ago
Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
GlobeNewswire
2 months ago
Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
Compare IRAA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRAA Iris Acquisition Corp - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.